Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ALK-positive Non-small Cell Lung Cancer (NSCLC) Clear all
Recruiting Phase 1 Interventional

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Interventions
gilteritinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Fullerton, California • Orange, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Available No phase listed Expanded access

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

NCT04146571
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive
Interventions
Ensartinib
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Stanford, California • Bethesda, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

NCT01625234
View directory record Official record
Conditions
Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions
Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
14
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Active, not recruiting Phase 3 Interventional

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT02201992
View directory record Official record
Conditions
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1613
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

NCT07567352
View directory record Official record
Conditions
Non-Small-Cell Lung, ALK-positive Advanced NSCLC, ALK-positive Non-small-cell Lung Cancer, ALK-positive NSCLC
Interventions
lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

NCT02336451
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer
Interventions
Ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • South Bend, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 23, 2026, 7:38 AM EDT
Recruiting Not applicable Interventional

Patient-centered, Optimal Integration of Survivorship and Palliative Care

NCT04900935
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, ALK-positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer, Palliative Care, Survivorship
Interventions
POISE
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

NCT02513667
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer
Interventions
Ceritinib, Stereotactic ablative body radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Jul 23, 2026, 7:38 AM EDT
Completed No phase listed Observational Results available

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

NCT04351334
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Alectinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT01562015
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

NCT03131206
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Thyroid Cancer
Interventions
Alectinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Irvine, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT02299505
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Fayetteville, Arkansas • Loma Linda, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Jul 23, 2026, 7:38 AM EDT
Recruiting Phase 3 Interventional

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Interventions
Neladalkib (NVL-655), Alectinib
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Glendale, Arizona • Newport Beach, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

NCT03088930
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Crizotinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 4 Interventional Results available

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

NCT04362072
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Active, not recruiting Phase 4 Interventional

Lorlatinib Continuation Study

NCT05144997
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer, NSCLC
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

NCT03535740
View directory record Official record
Conditions
ALK-positive Advanced NSCLC
Interventions
Brigatinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Orange, California • Whittier, California • Pueblo, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

NCT02075840
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib, Crizotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
10
States / cities
Northridge, California • Redondo Beach, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Active, not recruiting Phase 3 Interventional

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT02767804
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
X-396 (ensartinib), crizotinib
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Athens, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

NCT01970865
View directory record Official record
Conditions
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Interventions
PF-06463922, Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
32
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1 Interventional Results available

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

NCT00585195
View directory record Official record
Conditions
Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
Interventions
PF-02341066, Rifampin, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
24
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 23, 2026, 7:38 AM EDT
Completed No phase listed Observational Results available

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

NCT03833934
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lorlatinib, Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
34
States / cities
Altamonte Springs, Florida • Brandon, Florida • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional

PF-07284892 in Participants With Advanced Solid Tumors

NCT04800822
View directory record Official record
Conditions
Solid Tumor
Interventions
PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 7:38 AM EDT